KRAS and metastatic colorectal cancer: Given that KRAS4b mutations are associated with treatment-resistant tumors in metastatic colorectal cancer [6, 7], the KRAS4b-PDEδ complex has been suggested as a potential target for the generation of new cancer therapeutics [4].